Nobivac DHP lyophilisate and solvent for suspension for injection for dogs

Authorised

- Canine distemper virus, strain Onderstepoort, Live
- Canine adenovirus 2, strain Manhattan LPV3, Live
- Canine parvovirus, strain 154, Live

Product identification

Medicine name:
Nobivac DHP lyophilisate and solvent for suspension for injection for dogs
Nobivac DHP vet.

Active substance:
Canine distemper virus, strain Onderstepoort, Live

Canine adenovirus 2, strain Manhattan LPV3, Live

Canine parvovirus, strain 154, Live

Target species:
Dog

Route of administration:
Subcutaneous use

Product details

Active substance and strength:

Canine distemper virus, strain Onderstepoort, Live
10000.00 50% tissue culture infectious dose / 1.00 millilitre(s)

Canine adenovirus 2, strain Manhattan LPV3, Live
10000.00 50% tissue culture infectious dose / 1.00 millilitre(s)

Canine parvovirus, strain 154, Live
10000000.00 50% tissue culture infectious dose / 1.00 millilitre(s)

Pharmaceutical form:
Lyophilisate and solvent for suspension for injection

Withdrawal period by route of administration:

Subcutaneous use:

- **Dog**

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI07AD02

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:
Valid

Authorised in:
Norway

Package description:
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Plastic box containing 10 single dose vials of diluent.
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Plastic box containing 50 single dose vials of diluent.
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Plastic box containing 50 single dose vials of vaccine.

Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Plastic box containing 10 single dose vials of vaccine.
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Plastic box containing 50 single dose vials. The diluent is packed together with the vaccine.
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Plastic box containing 10 single dose vials. The diluent is packed together with the vaccine.
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Cardboard box containing 10 single dose vials of diluent.
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Cardboard box containing 50 single dose vials of diluent.
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Cardboard box containing 50 single dose vials of vaccine.
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Cardboard box containing 10 single dose vials of vaccine.
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Cardboard box containing 50 single dose vials. The diluent is packed together with the vaccine.
Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Cardboard box containing 10 single dose vials. The diluent is packed together with the vaccine.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Intervet International B.V.

Marketing authorisation date:
12/10/2005

Manufacturing sites for batch release:
Intervet International B.V.

Responsible authority:
Norwegian Medical Products Agency

Authorisation number:
05-3333

Date of authorisation status change:
12/11/2009

Reference member state:
Ireland

Procedure number:
IE/V/0161/001

Concerned member states:
Netherlands Norway United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

ie-puar-mr-iev0161001-nobivac-dhp-lyophilisate-and-solvent-for-suspensio-en.pdf

---